Neuronetics earnings release, August 11, 2026

Neuronetics, Inc. (STIM) · Form 8-K, Item 2.02 · Filed · SEC filing

Neuronetics Reports Second Quarter 2026 Financial and Operating Results

MALVERN, PA., August 11, 2026 – Neuronetics, Inc. (NASDAQ: STIM) (the “Company” or “Neuronetics”), a leader in interventional mental health that combines its NeuroStar®

TMS technology with direct patient care through the Greenbrook network of interventional psychiatry clinics, today announced its financial and operating results for the second quarter of 2026.

Second Quarter 2026 Financial Highlights

Recent Operational

Highlights

“This was a quarter of real operational progress, and meaningful steps toward our goal of sustained profitability and positive net cash flow from operations and investing,” said Dan Reuvers, President and Chief Executive Officer of Neuronetics. “For some time, NeuroStar has not competed to its full potential, and we are changing that by broadening how customers can access our technology while we continue to drive operational gains across the Greenbrook clinics. We also strengthened our leadership team, adding proven talent in key roles. The combination of a leading TMS platform and a national care network is what sets

Neuronetics apart, and it positions us to lead as new interventional therapies come to market. There is more work ahead, but I am encouraged by the traction we are beginning to demonstrate.”

Second Quarter 2026 Financial and Operating Results for the Three Months Ended June 30, 2026

Total revenue for the three months ended June 30, 2026 was $41.6 million, an increase of $3.5 million, or 9.1%, compared to the three months ended June 30, 2025 of $38.1 million. The increase was primarily driven by higher Greenbrook revenue, which increased to $26.9 million in the second quarter of 2026 from $23.0 million in the second quarter of 2025, reflecting continued growth of the Greenbrook business.

Gross margin increased from 46.6% for the three months ended June 30, 2025 to 51.1% for the three months ended June 30, 2026. The increase in gross margin was driven by the positive impact of our new go-to-market strategy, as well as improved revenue cycle management within the Greenbrook clinics.

Operating expenses during the second quarter of 2026 were $22.7 million, a decrease of $3.1 million, or 12%, compared to $25.8 million in the second quarter of 2025, primarily attributable to lower general and administrative expenses and lower sales and marketing expenses.

Loss from operations during the second quarter of 2026 was $1.5 million, a decrease of $6.6 million, as compared to a loss of $8.1 million in the second quarter of 2025. Adjusted EBITDA during the second quarter of 2026 was $0.3 million, an increase of $5.9 million compared to a loss of $5.6 million in the second quarter of 2025.

Net loss for the second quarter of 2026 was $3.4 million, or $0.05 per share, as compared to $10.1 million, or $0.15 per share, in the second quarter of 2025. Net loss per share was based on 73,129,107 and 66,180,069 weighted average common shares outstanding for the second quarters of 2026 and 2025, respectively.

As of June 30, 2026, the Company held $25 million in total cash, consisting of cash and cash equivalents of $19.2 million and $5.8 million of restricted cash, compared to total cash of $34.1 million as of December 31, 2025.

Strengthened Leadership Team

The Company made a series of changes to strengthen its senior leadership team and align its structure with the Company’s priorities. Nir Naor was appointed Executive Vice President, Chief Financial Officer, Corporate Secretary, and Treasurer, bringing more than 20 years of finance leadership across medical device and care-delivery businesses, including experience guiding a company to profitability and positive cash flow. Cory Anderson, a five-year veteran of the Company, was promoted to Executive Vice President and General Manager of Greenbrook, reflecting the growing importance of the clinic business. Rob Greene joined as

Senior Vice President, Sales, bringing extensive commercial leadership across healthcare and medical technology, including capital equipment and service, to support the Company’s expanded NeuroStar go-to-market models.

Business Outlook

For the full year 2026, Neuronetics expects:

Non-GAAP

Financial Measures (Unaudited)

Operating Expense Guidance: FY 2026

The following table presents the Company’s reconciliation between Operating Expenses and Operating Expenses less

Non-cash

Stock- Based Compensation. This adjusted guidance is based on assumptions that management believes are reasonable under the circumstances. However, they are not necessarily indicative of the Company’s future performance. Operating Expenses less Stock Based Compensation are projected Operating Expenses for the fiscal year 2026, less non-cash stock-based compensation.

Webcast and Conference Call Information

The conference call will be broadcast live in listen-only mode via webcast at https://edge.media-server.com/mmc/p/7ri4xna9.

To listen to the conference call on your telephone, participants may register for the call here. While it is not required, it is recommended you join 10 minutes prior to the event start

About Neuronetics

Neuronetics, Inc. is a leader in interventional mental health, combining innovative treatment technologies with direct patient care. Through its NeuroStar®

Advanced Therapy system, the Company is a leading provider of transcranial magnetic stimulation (“TMS”) treatment and, through Greenbrook TMS Inc. (“Greenbrook”), operates one of the largest interventional psychiatry clinic networks in the United States, offering both TMS and SPRAVATO® therapies. NeuroStar Advanced Therapy is a non-drug, noninvasive treatment that can improve the quality of life for people suffering from neurohealth... (truncated) is the leading TMS treatment for major depressive disorder (“MDD”) in adults and is backed by what we believe is the largest clinical data set of any TMS treatment system for depression. Greenbrook treatment centers also offer SPRAVATO®

(esketamine) nasal spray, a prescription medicine indicated for the treatment of treatment-resistant depression (“TRD”) in adults as monotherapy or in conjunction with an oral antidepressant. It is also indicated for depressive symptoms in adults with MDD with acute suicidal ideation or behavior in conjunction with an oral antidepressant.¹

The NeuroStar Advanced Therapy System is cleared by the U.S. Food and Drug

Administration for adults with MDD, as an adjunct for adults with obsessive-compulsive disorder, to decrease anxiety symptoms in adult patients with MDD that may exhibit comorbid anxiety symptoms (anxious depression), and as a first line adjunct for the treatment of MDD in adolescent patients aged

15-21.

For safety information and indications for use, visit

NeuroStar.com.

“Safe harbor” statement under the Private Securities Litigation Reform Act of 1995:

Financial statements

Income Statement

Second Quarter 2026 Financial and Operating Results for the Three Months Ended June 30, 2026

Revenues by Segments – Three Months Ended June 30, – 2026 – Amount – (Unaudited; in thousands, except percentages)Revenues by Segments – Three Months Ended June 30, – 2025 – Amount – (Unaudited; in thousands, except percentages)% Change – (Unaudited; in thousands, except percentages)
NeuroStar revenue14,67715,084)%
Greenbrook revenue26,89123,02416.8%
Total revenues41,56838,1089.1%

Income Statement

Three Months ended — (Unaudited; In thousands, except per share data)

Three Months ended – June 30, – 2026Three Months ended – June 30, – 2025Six months ended – June 30, – 2026Six months ended – June 30, – 2025
RevenuesNeuroStar14,67715,08427,60228,400
RevenuesGreenbrook26,89123,02448,42041,683
RevenuesTotal Revenue41,56838,10876,02270,083
Cost of revenuesNeuroStar3,3124,3116,1707,461
Cost of revenuesGreenbrook17,03316,03932,47529,126
Cost of revenuesTotal Cost of revenues20,34520,35038,64536,587
Cost of revenuesGross profit21,22317,75837,37733,496
Operating expenses:Sales and marketing9,98411,86820,72123,867
Operating expenses:General and administrative11,40412,15024,45225,287
Operating expenses:Research and development1,3361,7982,7003,414
Operating expenses:Total operating expenses22,72425,81647,87352,568
Operating expenses:Loss from operations-1,501-8,058-10,496-19,072
Other (income) expense:Interest expense2,1251,9694,3913,891
Other (income) expense:Loss on extinguishment of debt539
Other (income) expense:Other income, net-162-188-1,182-435
Other (income) expense:Net loss-3,464-9,839-14,244-22,528
Other (income) expense:Less: Net gain (loss) attributable to non-controlling interest-25281-15267
Other (income) expense:Net loss attributable to Neuronetics stockholders-3,439-10,120-14,229-22,795
Other (income) expense:Net loss per share of common stock outstanding, basic and diluted attributable to Neuronetics stockholders-0.05-0.15-0.2-0.36
Other (income) expense:Weighted average common shares outstanding, basic and diluted73,12966,18071,36963,835

Income Statement

Three Months ended June 30, — The following table reconciles reported net loss to EBITDA and adjusted EBITDA: (in thousands)

Three Months ended June 30, – 2026Three Months ended June 30, – 2025Six months ended June 30, – 2026Six months ended June 30, – 2025
Net loss attributable to Neuronetics stockholders’-3,439-10,120-14,229-22,795
Interest expense, net1,9631,7813,2093,456
Depreciation and amortization7299011,4741,812
EBITDA-747-7,438-9,546-17,527
Stock based compensation (Note. 1)6881,8142,3653,258
Loss on extinguishment of debt (Note. 2)539
Restructuring (Note. 3)313313
Adjusted EBITDA254-5,624-6,329-14,269

Balance Sheet

December 31, — (Unaudited; In thousands, except per share data)

June 30, – 2026December 31, – 2025
Current assets:Cash and cash equivalents19,19728,134
Current assets:Restricted cash5,7506,000
Current assets:Accounts receivable, net of allowance for credit losses of $553 and $1,043 as of June 30, 2026 and December 31, 2025, respectively15,95516,469
Current assets:Inventory5,5024,327
Current assets:Current portion of net investments in sales-type leases233225
Current assets:Current portion of prepaid commission expense2,7733,050
Current assets:Current portion of note receivables315424
Current assets:Prepaid expenses and other current assets3,5052,922
Current assets:Total current assets53,23061,551
Current assets:Property and equipment, net3,4644,466
Current assets:Goodwill23,62223,622
Current assets:Intangible assets, net17,42018,149
Current assets:Operating lease right-of-use assets23,91323,560
Current assets:Net investments in sales-type leases6598
Current assets:Prepaid commission expense6,9807,972
Current assets:Long-term notes receivable43151
Current assets:Other assets2,7921,982
Current assets:Total assets131,529141,551
Current liabilities:Accounts payable12,41910,739
Current liabilities:Accrued expenses8,92912,316
Current liabilities:Current portion of deferred revenue1,143753
Current liabilities:Deferred and contingent consideration250500
Current liabilities:Other payables425652
Current liabilities:Current portion of operating lease liabilities5,1435,561
Current liabilities:Total current liabilities28,30930,521
Current liabilities:Long-term debt, net61,51965,807
Current liabilities:Other long term liabilities142
Current liabilities:Deferred revenue5848
Current liabilities:Operating lease liabilities19,86118,935
Current liabilities:Total liabilities109,889115,311
Equity:Common stock, $0.01 par value: 250,000 shares authorized; 76,193 and 68,994 shares issued and outstanding on June 30, 2026 and December 31, 2025, respectively762690
Equity:Additional paid-in capital490,239480,475
Equity:Accumulated deficit-473,151-458,787
Equity:Total Stockholders’ equity17,85022,378
Equity:Non-controlling interest3,7903,862
Equity:Total equity21,64026,240
Equity:Total liabilities and equity131,529141,551
Full release

Certain statements in this press release, including the documents incorporated by reference herein, include “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), Section 21E of the Securities Exchange Act of 1934, as amended, which are intended to be covered by the safe harbors created by those laws and other applicable laws and “forward-looking information” within the meaning of applicable Canadian securities laws. Statements in this press release that are not historical facts constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements may be identified by terms such as “may,” “will,” “would,” “should,” “expect,”

“plan,” “design,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,”

“predict,” “potential,” “outlook” or “continue” as well as the negative of these terms and similar expressions. These statements include those relating to the Company’s business outlook and current expectations for upcoming quarters and fiscal year 2026, including with respect to revenue, expenses, growth, and any statements of assumptions underlying any of the foregoing items. These statements are subject to significant risks and uncertainties and actual results could differ materially from those projected. The Company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. These risks and uncertainties include, without limitation, risks and uncertainties related to: the effect of the transaction with Greenbrook on our business relationships; operating results and business generally; our ability to execute our business strategy; our ability to achieve or sustain profitable operations due to our history of losses; our reliance on the sale and usage of our NeuroStar Advanced Therapy System to generate revenues; the scale and efficacy of our salesforce; our ability to retain talent; availability of coverage and reimbursement from third-party payors for treatments using our products; physician and patient demand for treatments using our products; developments in respect of competing technologies and therapies for the indications that our products treat; product defects; our ability to obtain and maintain intellectual property protection for our technology; developments in clinical trials or regulatory review of the NeuroStar Advanced Therapy System for additional indications; developments in regulation in the U.S. and other applicable jurisdictions; potential effects of evolving and/or extensive government regulation; the terms of our credit facility; our self-sustainability; existing cash balance; our ability to achieve positive cash flows; and our ability to continue as a going concern. For a discussion of these and other related risks, please refer to the Company’s recent filings with the U.S. Securities and Exchange Commission (the “SEC”), which are available on the SEC’s website at www.sec.gov, including, without limitation, the factors described under the heading “Risk Factors” in Neuronetics’ Annual Report on Form

10-K for the fiscal year ended December 31, 2025 and the company’s Quarterly Report on Form

10-Q for the quarter ending June 30, 2026, as may be updated or supplemented by subsequent reports that Neuronetics has filed or files with the SEC. These forward-looking statements are based on the Company’s expectations and assumptions as of the date of this press release. Except as required by law, the Company undertakes no duty or obligation to update any forward-looking statements contained in this press release as a result of new information, future events, or changes in the Company’s expectations.

Investor Contact:

Mike Vallie or Mark Klausner

ICR Healthcare

443-213-0499 ir@neuronetics.com

Media Contact:

EvolveMKD

646-517-4220

NeuroStar@evolvemkd.com

NEURONETICS, INC.

Consolidated Statements of Operations

(Unaudited; In thousands, except per share data)

NEURONETICS, INC.

Consolidated Balance Sheets

(Unaudited; In thousands, except per share data)

NEURONETICS, INC.

Consolidated Statements of Cash Flows

(Unaudited; In thousands)

Non-GAAP

Financial Measures (Unaudited)

EBITDA and adjusted EBITDA are not measures of financial performance under generally accepted accounting principles in the U.S. (“GAAP”), and should not be construed as a substitute for, or superior to, GAAP net loss. However, management uses both the GAAP and non-GAAP financial measures internally to evaluate and manage the Company’s operations and to better understand its business. Further, management believes that the addition of the non-GAAP... (truncated)aningful supplementary information to, and facilitates analysis by, investors in evaluating the Company’s financial performance, results of operations and trends. The Company’s calculation of EBITDA and adjusted EBITDA may not be comparable to similarly designated measures reported by other companies, because companies and investors may differ as to what type of events warrant adjustment.

The following table reconciles reported net loss to

EBITDA and adjusted EBITDA:

Footnotes

References

1 The effectiveness of SPRAVATO in preventing suicide or in reducing suicidal ideation or behavior has not been demonstrated. Use of SPRAVATO does not preclude the need for hospitalization if clinically warranted, even if patients experience improvement after an initial dose of SPRAVATO. For more important safety information about SPRAVATO, please visit spravatohcp.com.

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Neuronetics earnings · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.